Evaxion Biotech Ownership 2024 | Who Owns Evaxion Biotech Now?
Institutional Ownership
15.81%
Insider Ownership
15.53%
Retail Ownership
68.67%
Institutional Holders
10.00
Evaxion Biotech Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | - | - | - | -8,997 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -386 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -14,000 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -2,909 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -1,300 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -277 | -100.00% | - | Mar 31, 2024 |
| BEACON CAPITAL MANAGEMENT, LLC | - | - | - | -48,633 | -100.00% | - | Mar 31, 2024 |
| LM ADVISORS LLC | - | - | - | -337,336 | -100.00% | - | Mar 31, 2024 |
Evaxion Biotech's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | - | - | - | -8,997 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -386 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -14,000 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -2,909 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -1,300 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -277 | -100.00% | - | Mar 31, 2024 |
| BEACON CAPITAL MANAGEMENT, LLC | - | - | - | -48,633 | -100.00% | - | Mar 31, 2024 |
| LM ADVISORS LLC | - | - | - | -337,336 | -100.00% | - | Mar 31, 2024 |
The largest Evaxion Biotech shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Evaxion Biotech (EVAX), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| UBS GROUP AG | - | - | - | -277 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -386 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -1,300 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -2,909 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -8,997 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -14,000 | -100.00% | - | Mar 31, 2024 |
| BEACON CAPITAL MANAGEMENT, LLC | - | - | - | -48,633 | -100.00% | - | Mar 31, 2024 |
| LM ADVISORS LLC | - | - | - | -337,336 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Evaxion Biotech's largest institutional buyer is UBS GROUP AG. The company purchased -0.28K stocks of EVAX, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LM ADVISORS LLC | - | - | - | -337,336 | -100.00% | - | Mar 31, 2024 |
| BEACON CAPITAL MANAGEMENT, LLC | - | - | - | -48,633 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -14,000 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -8,997 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -2,909 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -1,300 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -386 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -277 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Evaxion Biotech's biggest institutional seller is LM ADVISORS LLC. The company sold -0.34M shares of EVAX, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LM ADVISORS LLC | - | - | - | -337,336 | -100.00% | - | Mar 31, 2024 |
| BEACON CAPITAL MANAGEMENT, LLC | - | - | - | -48,633 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -14,000 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | - | - | - | -8,997 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -2,909 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -1,300 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -386 | -100.00% | - | Mar 31, 2024 |
| UBS GROUP AG | - | - | - | -277 | -100.00% | - | Mar 31, 2024 |
Evaxion Biotech's largest sold out institutional shareholder by shares sold is LM ADVISORS LLC, sold -0.34M shares, valued at -, as of undefined.
Evaxion Biotech Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| ETF Managers Trust | 0.00% | 7,020 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 2,428 | - | - | Feb 29, 2024 |
Evaxion Biotech's largest mutual fund holder by % of total assets is "ETF Managers Trust", owning 7.02K shares, compromising 0.00% of its total assets.
Evaxion Biotech Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Dec, 23 | 10 | -9.09% |
| 30 Sep, 23 | 11 | 10.00% |
| 30 Jun, 23 | 10 | -9.09% |
| 31 Mar, 23 | 11 | - |
| 31 Dec, 22 | 11 | 22.22% |
| 30 Sep, 22 | 9 | -18.18% |
| 30 Jun, 22 | 11 | -21.43% |
| 31 Mar, 22 | 14 | -6.67% |
| 31 Dec, 21 | 15 | 114.29% |
| 30 Sep, 21 | 7 | 16.67% |
| 30 Jun, 21 | 6 | -40.00% |
| 31 Mar, 21 | 10 | - |
As of 31 Dec 23, 10 institutions are holding Evaxion Biotech's shares, representing a decrease of -9.09% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Dec, 23 | 437,168 | 226.96% |
| 30 Sep, 23 | 133,705 | -17.13% |
| 30 Jun, 23 | 161,337 | -37.52% |
| 31 Mar, 23 | 258,202 | 177.95% |
| 31 Dec, 22 | 92,896 | -35.15% |
| 30 Sep, 22 | 143,252 | -36.86% |
| 30 Jun, 22 | 226,864 | -66.56% |
| 31 Mar, 22 | 678,470 | -37.05% |
| 31 Dec, 21 | 1,077,814 | 216.74% |
| 30 Sep, 21 | 340,282 | -22.58% |
| 30 Jun, 21 | 439,553 | -50.28% |
| 31 Mar, 21 | 883,983 | - |
Evaxion Biotech (EVAX) has 437.17K shares outstanding as of 31 Dec 23, up 226.96% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Dec, 23 | 15.81% | 6474.32% |
| 30 Sep, 23 | 0.49% | 126.19% |
| 30 Jun, 23 | 0.63% | 62.39% |
| 31 Mar, 23 | 1.00% | 673.06% |
| 31 Dec, 22 | 0.39% | 106.79% |
| 30 Sep, 22 | 0.60% | 66.37% |
| 30 Jun, 22 | 0.95% | 11.09% |
| 31 Mar, 22 | 2.93% | 11.84% |
| 31 Dec, 21 | 4.97% | 162.39% |
| 30 Sep, 21 | 1.75% | 33.39% |
| 30 Jun, 21 | 2.29% | 9.35% |
| 31 Mar, 21 | 4.95% | - |
As of 31 Dec 23, Evaxion Biotech is held by 15.81% institutional shareholders, representing a 6474.32% growth compared to 30 Sep 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Dec, 23 | 5 | 66.67% |
| 30 Sep, 23 | 3 | 50.00% |
| 30 Jun, 23 | 2 | -75.00% |
| 31 Mar, 23 | 8 | 33.33% |
| 31 Dec, 22 | 6 | 200.00% |
| 30 Sep, 22 | 2 | -33.33% |
| 30 Jun, 22 | 3 | -50.00% |
| 31 Mar, 22 | 6 | -53.85% |
| 31 Dec, 21 | 13 | 225.00% |
| 30 Sep, 21 | 4 | 100.00% |
| 30 Jun, 21 | 2 | -80.00% |
| 31 Mar, 21 | 10 | - |
5 institutional shareholders have increased their position in EVAX stock as of 31 Dec 23 compared to 3 in the previous quarter (a 66.67% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Dec, 23 | 2 | -50.00% |
| 30 Sep, 23 | 4 | -33.33% |
| 30 Jun, 23 | 6 | 500.00% |
| 31 Mar, 23 | 1 | -50.00% |
| 31 Dec, 22 | 2 | -33.33% |
| 30 Sep, 22 | 3 | -25.00% |
| 30 Jun, 22 | 4 | -20.00% |
| 31 Mar, 22 | 5 | - |
| 31 Dec, 21 | - | -100.00% |
| 30 Sep, 21 | 2 | -33.33% |
| 30 Jun, 21 | 3 | - |
| 31 Mar, 21 | - | - |
2 institutional shareholders have reduced their position in EVAX stock as of 31 Dec 23 compared to 4 in the previous quarter (a -50.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Dec, 23 | 10 | -9.09% | 437,168 | 226.96% | 15.81% | 6474.32% | 5 | 66.67% | 2 | -50.00% |
| 30 Sep, 23 | 11 | 10.00% | 133,705 | -17.13% | 0.49% | 126.19% | 3 | 50.00% | 4 | -33.33% |
| 30 Jun, 23 | 10 | -9.09% | 161,337 | -37.52% | 0.63% | 62.39% | 2 | -75.00% | 6 | 500.00% |
| 31 Mar, 23 | 11 | - | 258,202 | 177.95% | 1.00% | 673.06% | 8 | 33.33% | 1 | -50.00% |
| 31 Dec, 22 | 11 | 22.22% | 92,896 | -35.15% | 0.39% | 106.79% | 6 | 200.00% | 2 | -33.33% |
| 30 Sep, 22 | 9 | -18.18% | 143,252 | -36.86% | 0.60% | 66.37% | 2 | -33.33% | 3 | -25.00% |
| 30 Jun, 22 | 11 | -21.43% | 226,864 | -66.56% | 0.95% | 11.09% | 3 | -50.00% | 4 | -20.00% |
| 31 Mar, 22 | 14 | -6.67% | 678,470 | -37.05% | 2.93% | 11.84% | 6 | -53.85% | 5 | - |
| 31 Dec, 21 | 15 | 114.29% | 1,077,814 | 216.74% | 4.97% | 162.39% | 13 | 225.00% | - | -100.00% |
| 30 Sep, 21 | 7 | 16.67% | 340,282 | -22.58% | 1.75% | 33.39% | 4 | 100.00% | 2 | -33.33% |
| 30 Jun, 21 | 6 | -40.00% | 439,553 | -50.28% | 2.29% | 9.35% | 2 | -80.00% | 3 | - |
| 31 Mar, 21 | 10 | - | 883,983 | - | 4.95% | - | 10 | - | - | - |
Evaxion Biotech Peer Ownership
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| RNAZ | TransCode Therapeutics, Inc. |
| LABP | Landos Biopharma, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| SGTX | Sigilon Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| EFTR | eFFECTOR Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ALLR | Allarity Therapeutics, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
EVAX Ownership FAQ
Who Owns Evaxion Biotech?
Evaxion Biotech is owned by institutional shareholders (15.81%), insiders (15.53%), and public (68.67%). The largest institutional shareholder of Evaxion Biotech is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is ETF Managers Trust (0.00% of total shares).
Who are the major institutional shareholders of Evaxion Biotech?
Evaxion Biotech's major institutional shareholders are JPMORGAN CHASE & CO, GROUP ONE TRADING, L.P., RENAISSANCE TECHNOLOGIES LLC, RHUMBLINE ADVISERS, and CITADEL ADVISORS LLC. The top five shareholders own together 0% of the company's share outstanding.
How many Evaxion Biotech shareholders are there?
As of Dec 2023, there are 10 institutional shareholders of Evaxion Biotech.
What percentage of Evaxion Biotech is owned by JPMORGAN CHASE & CO?
JPMORGAN CHASE & CO owns 0 shares of Evaxion Biotech, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).
What percentage of Evaxion Biotech is owned by GROUP ONE TRADING, L.P?
As of Mar 2024, GROUP ONE TRADING, L.P holds 0 shares of Evaxion Biotech (EVAX), compromising 0% of the company, valued at $0.
What percentage of Evaxion Biotech is owned by RENAISSANCE TECHNOLOGIES LLC?
RENAISSANCE TECHNOLOGIES LLC is the third largest holder of Evaxion Biotech. The company owns 0 of the company's shares outstanding (worth $0).